Barra F, Laganà AS, Casarin J, Ghezzi F, Ferro Desideri L, Scala C, Ferrero S. Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? Int J Fertil Steril 2019;13:89-92. http://ijfs.ir/journal/article/abstract/5736
Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation
Scala C, Leone Roberti Maggiore U, Barra F, Tantari M, Ferrero S. Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation. Medicina (Kaunas);55(9). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780829/
Preoperative Hormonal Treatment Before Laparoscopic Approach for Uterine Fibroids: Do We Need It?
Barra F, Evangelisti G, Ferrero S. Preoperative Hormonal Treatment Before Laparoscopic Approach for Uterine Fibroids: Do We Need It? J Invest Surg. 2019 Aug 28:1-3. https://www.tandfonline.com/doi/full/10.1080/08941939.2019.1655118
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs
Moioli M, Barra F, Maramai M, Valenzano Menada M, Vellone VG, Costantini S, Ferrero S. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs. Expert Opin Investig Drugs 2019;28:1025-1029. https://www.tandfonline.com/doi/abs/10.1080/13543784.2019.1693999?journalCode=ieid20
Application of failure mode and effect analysis in total laparoscopic hysterectomy in benign conditions
Lijoi D, Farina M, Puppo A, Novelli A, Ferrero S. Application of failure mode and effect analysis in total laparoscopic hysterectomy in benign conditions. Minerva Ginecol. 2019 Aug;71(4):272-280. https://www.minervamedica.it/it/riviste/minerva-ginecologica/articolo.php?cod=R09Y2019N04A0272
Relugolix for the treatment of uterine fibroids
Barra F, Seca M, Della Corte L, Giampaolino P, Ferrero S. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc) 2019;55:503-512. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=3020179
Cervical intraepithelial neoplasia in women who had vaccination against HPV
Bogani G, Serati M, Maggiore ULR, Ditto A, Gardella B, Ferrero S, Spinillo A, Ghezzi F, Raspagliesi F. Cervical intraepithelial neoplasia in women who had vaccination against HPV. Int J Gynaecol Obstet 2019;147:233-237. https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.12934
L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
Orecchia P, Balza E, Pietra G, Conte R, Bizzarri N, Ferrero S, Mingari MC, Carnemolla B. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. Cancers (Basel). 2019;11(9). https://www.mdpi.com/2072-6694/11/9/1232
Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?
Ferrero S, Vellone VG, Barra F, Scala C. Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance? Gynecol Obstet Invest 2019;84:313-325. https://www.karger.com/Article/FullText/495347
Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis
Barra F, Romano A, Grandi G, Facchinetti F, Ferrero S. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. Expert Opin Investig Drugs 2019;28:501-504. https://www.tandfonline.com/doi/abs/10.1080/13543784.2019.1618269?journalCode=ieid20